A Randomized Controlled Clinical Trial Comparing Tricalcium Silicate and Formocresol Pulpotomies Followed for Two to...

Area of Science:

• Dental Materials Science
• Pediatric Dentistry
• Regenerative Endodontics

Background:

• Tricalcium silicate (Biodentine) is a novel synthetic restorative cement with demonstrated efficacy in pulpotomy.
• Formocresol has been a traditional standard for pulpotomy treatments.
• Evaluating long-term outcomes of newer materials against established ones is crucial for clinical practice.

Purpose of the Study:

• To compare the long-term clinical success of tricalcium silicate versus formocresol in pulpotomies of human primary molars.
• To assess the efficacy and safety of Biodentine as a pulpotomy agent in a pediatric population.

Main Methods:

• A randomized clinical control trial was conducted on healthy children aged two to ten years.
• Pulpotomy treatments on primary molars were performed using either tricalcium silicate or formocresol as pulp dressing.
• Clinical data were collected and analyzed at follow-up intervals up to 48 months.

Main Results:

• The overall success rate for pulpotomies was 94.4%.
• Tricalcium silicate achieved a success rate of 97.3% (36/37 teeth).
• Formocresol achieved a success rate of 91.4% (32/35 teeth).

Conclusions:

• Tricalcium silicate exhibited a higher success rate than formocresol in primary molar pulpotomies, although not statistically significant.
• Biodentine presents a favorable alternative for pulpotomy treatments in primary teeth with a high success rate over two to four years.